

REMARKS

Applicants submit this Amendment to insert the required references to SEQ ID NOS of the Sequence Listing filed concurrently herewith, to delete the Sequence Listing filed previously, and to indicate the insertion point for the Sequence Listing filed concurrently herewith. Applicants respectfully request examination on the merits of this application. Receipt of the initial Office Action on the merits is awaited.

Respectfully submitted,

August 29, 2001
Date

FOLEY & LARDNER
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5109
Telephone: (202) 672-5569
Facsimile: (202) 672-5399

for / Phillip J. Artale
Stephen B. Maebius
Registration No. 35,264

Reg. No.
38,819

MARKED UP VERSION ATTACHED TO AMENDMENT

In the specification:

Marked up version of specification starting at page 19, paragraph 3, lines 21-34:

FIGURE 8. Comparison of the N-terminal amino acid sequences of the OZF proteins according to their origin and their reactivity with the monoclonal antibodies. Comparison of the N-terminal region of two alleles of the human OZF protein (SEQ ID NOS: 3 and 4, respectively in order of appearance) (hu-OZF) which differ by a polymorphism at position 8 (K/R) with the OZF protein of murine (SEQ ID NO:6) (mu-OZF) and bovine (SEQ ID NO:5) (bo-OZF) origin. The sequence of the synthetic peptide (SEQ ID NO:1) used in the competitive inhibition experiments is indicated above (PEPTIDE). The tyrosine residue at position 10 is underlined. The sequence of the carrier protein MBP is indicated in small upper case letters for the MBP-OZF protein (SEQ ID NO:2). The H/C consensus link ("H/C link") precede the first zinc finger corresponds to position 11-17.